PMX

Planet Fitness Flexes Its Marketing Muscle -- Names Publicis Groupe as New Agency of Record

Retrieved on: 
Wednesday, September 1, 2021
Industry, Company, My Gym Children's Fitness Center, District, Leadership, Ascential, Efficiency, ATOT, Planet Fitness, Publicis, Man, Health, Marketing, RFP, NYSE, Awareness, Multimedia, Octane Fitness, LLC v. ICON Health & Fitness, Inc., PMX, Partnership, Creativity, CEO, Woman, Medialink, Retail, Health insurance, Online shopping

Team Lift, a bespoke agency solution,was created specifically for Planet Fitness to support marketing strategy, centralized data and analytics, media planning and buying, creative, and brand partnerships.

Key Points: 
  • Team Lift, a bespoke agency solution,was created specifically for Planet Fitness to support marketing strategy, centralized data and analytics, media planning and buying, creative, and brand partnerships.
  • "As an industry leader and a top U.S. advertising spender, we are thrilled to welcome Publicis Groupe into the Planet Fitness family as our new agency of record."
  • "Publicis Groupe is thrilled to innovate alongside Planet Fitness to find new ways to connect with their broad and growing customer base."
  • More than 95% of Planet Fitness stores are owned and operated by independent business men and women.

Spectral Medical Announces its Participation at Upcoming Investor Conferences

Retrieved on: 
Monday, August 23, 2021
Sepsis, U.S. FDA, GLOBE, EDT, Spectral, Renal replacement therapy, RRT, Septic shock, PMX, Risk, News, Patient, SAMI, Health Canada, Conference, TSX, FDA, Federal Food, Drug, and Cosmetic Act, Toronto Stock Exchange, Pharmaceutical industry, Medical device

Alliance Global Partners Fall Biotech & Specialty Pharma Conference, October 13, 2021

Key Points: 
  • Alliance Global Partners Fall Biotech & Specialty Pharma Conference, October 13, 2021
    Presentation times will be announced closer to the date of each conference.
  • Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin (PMX).
  • Spectral, through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new set of proprietary platforms addressing renal replacement therapy (RRT) across the dialysis spectrum.
  • While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect.

Spectral Medical Announces Internal Reorganization of its Wholly Owned Subsidiary Dialco Medical to Enhance Operations and Accelerate Commercialization

Retrieved on: 
Monday, August 9, 2021
SAMI, Federal Food, Drug, and Cosmetic Act, U.S. FDA, GLOBE, Toronto Stock Exchange, FDA, CEO, QA, Sepsis, PMX, Growth, News, Risk, Dialysis, Patient, TSX, EDT, Peritoneal dialysis, RRT, Health Canada, Renal replacement therapy, Septic shock, Company, Pharmaceutical industry, Medical device

TORONTO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (Spectral or the Company) (TSX: EDT), today announced an internal reorganization to strengthen the core competencies and management of its wholly owned subsidiary, Dialco Medical Inc. (Dialco).

Key Points: 
  • TORONTO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (Spectral or the Company) (TSX: EDT), today announced an internal reorganization to strengthen the core competencies and management of its wholly owned subsidiary, Dialco Medical Inc. (Dialco).
  • In connection with the reorganization, the Company announces that Gualtiero Guadagni has resigned as President of Dialco to pursue other opportunities.
  • Chris Seto, CEO of Spectral, stated, We are making tremendous progress advancing our Dialco subsidiary, and believe this internal reorganization will help strengthen the organization in advance of key upcoming milestones.
  • Spectral, through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new set of proprietary platforms addressing renal replacement therapy (RRT) across the dialysis spectrum.

Spectral Medical to Present at the Q2 Virtual Investor Summit on May 17th

Retrieved on: 
Tuesday, May 11, 2021
Dimi, Talmud rabbis, Hemodialysis, RRT, PMX

The Q1 Investor Summit will take place virtually, featuring 100 companies and over 300 institutional and retail investors.\nTo request complimentary investor registration: please visit our website at www.investorsummitgroup.com .\nSpectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin\xe2\x84\xa2 ("PMX").

Key Points: 
  • The Q1 Investor Summit will take place virtually, featuring 100 companies and over 300 institutional and retail investors.\nTo request complimentary investor registration: please visit our website at www.investorsummitgroup.com .\nSpectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin\xe2\x84\xa2 ("PMX").
  • In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada.
  • "SAMI" is targeting the acute RRT market, while "DIMI" is targeting the chronic RRT market.
  • Dialco is currently pursuing regulatory approval for U.S. in-home use of "DIMI", which is based on the same RRT platform as "SAMI", but will be intended for home hemodialysis use.

Spectral Medical Engages Crescendo Communications to Provide Investor Relations Services in the United States

Retrieved on: 
Thursday, March 4, 2021
Medical specialties, Medicine, Clinical medicine, Intensive care medicine, Cable television in Canada, PMX, Pelmorex, Television technology, Septic shock, RRT, Food and Drug Administration, Renal replacement therapy

Spectrals Toraymyxin PMX endotoxin removal cartridge, combined with its EAA diagnostic, address a dramatically underserved $1.5 billion market opportunity with no competing FDA approved solutions.

Key Points: 
  • Spectrals Toraymyxin PMX endotoxin removal cartridge, combined with its EAA diagnostic, address a dramatically underserved $1.5 billion market opportunity with no competing FDA approved solutions.
  • We look forward to helping increase awareness within the US investment community, as Spectral advances towards a number of key milestones.
  • Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin (PMX).
  • Spectral, through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new proprietary platform, SAMI, targeting the renal replacement therapy (RRT) market.

Spectral Medical to participate at the upcoming H.C. Wainwright Global Life Sciences Conference

Retrieved on: 
Tuesday, March 2, 2021
RRT, Food and Drug Administration, PMX

A link to the presentation will be available under Events, Webcasts and Presentations in the investors section of Spectrals website at 7:00 a.m.

Key Points: 
  • A link to the presentation will be available under Events, Webcasts and Presentations in the investors section of Spectrals website at 7:00 a.m.
  • Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin (PMX).
  • PMX is approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 200,000 patients to date.
  • Spectral, through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new proprietary platform, SAMI, targeting the renal replacement therapy (RRT) market.

Inuvo’s IntentKey Uncovers Insights that Help Nonprofits Connect with the Right Donors

Retrieved on: 
Monday, December 14, 2020
Cable television in Canada, PMX, Pelmorex, Television technology, Fundraising

During the COVID-19 pandemic the adoption of social distancing guidelines has made it difficult for nonprofits, who rely more on traditional fundraisers.

Key Points: 
  • During the COVID-19 pandemic the adoption of social distancing guidelines has made it difficult for nonprofits, who rely more on traditional fundraisers.
  • The artificial intelligence technology behind the Intentkey has successfully allowed Forward PMX to reach users who looked most like their clients donors and had a high propensity to donate.
  • This experience has taught the IntentKey that donor audiences look very different from one client to another.
  • By understanding the nuances of these donors, we can work with Forward PMX to tailor creative messaging that resonates best with donor audiences.

Spectral Medical Inc. Closes Previously Announced $5.1 Million Public Offering of Units

Retrieved on: 
Thursday, June 18, 2020
Medical specialties, Medicine, Health, Intensive care medicine, Medical emergencies, RTT, Septic, Shock, Sepsis, PMX, Food and Drug Administration

TORONTO, June 18, 2020 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (Spectral or the Company) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, announced today that it has closed its previously announced marketed public offering of units of the Company (the Offered Units) for aggregate gross proceeds of $5.1 million (the Offering).

Key Points: 
  • TORONTO, June 18, 2020 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (Spectral or the Company) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, announced today that it has closed its previously announced marketed public offering of units of the Company (the Offered Units) for aggregate gross proceeds of $5.1 million (the Offering).
  • Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin (PMX).
  • Spectral, through its wholly owned subsidiary, Dialco Medical Inc.(Dialco), is also commercializing a new proprietary platform, SAMI, targeting the renal replacement therapy (RRT) market.
  • While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect.

Health Canada Issues an Interim Order for Spectral Medical’s PMX to Treat COVID-19 Patients

Retrieved on: 
Monday, April 20, 2020
Medical specialties, Intensive care medicine, Medicine, Respiratory diseases, Medical emergencies, Cable television in Canada, PMX, Pelmorex, Respiratory failure, Branches of biology

As part of the Interim Order process, the Health Minister determined that there is an urgent public health need for the importation or sale of PMX.

Key Points: 
  • As part of the Interim Order process, the Health Minister determined that there is an urgent public health need for the importation or sale of PMX.
  • Spectral and its manufacturing partner, collectively applied for the authorization for the Interim Order.
  • The Interim Order allows for the use of PMX to treat COVID-19 patients, particularly those with acute respiratory failure, diffuse alveolar damage or difficulty with maintaining oxygenation, in the presence of hypotensive shock.
  • There is a very strong scientific case for the use of PMX in COVID-19 patients.

US FDA Approves an Investigational Device Exemption for Spectral Medical PMX to Treat COVID-19 Patients Suffering from Septic Shock

Retrieved on: 
Tuesday, April 14, 2020
Medical specialties, Intensive care medicine, Medicine, Medical emergencies, PMX, Septic shock, Shock, Septic

There is a very strong scientific case for the use of PMX in COVID-19 patients.

Key Points: 
  • There is a very strong scientific case for the use of PMX in COVID-19 patients.
  • In previous publications, the use of PMX in septic shock patients has resulted in decreased dependency on ventilators, which is a serious issue during this COVID-19 pandemic.
  • Spectral now hopes to contribute more to the treatment of septic shock patients during this pandemic.
  • Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin (PMX).